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Abstract
In an attempt to disclose mechanisms of hepatocarci-
nogenesis and discover novel target molecules for
the diagnosis and treatment of hepatocellular carci-
nomas (HCCs), we previously analyzed expression
profiles of HCC tissues by means of human cDNA
microarray. Among the genes upregulated in tumor
tissues compared with their nontumor counterparts,
we focused on a novel gene, termed WDRPUH, and
characterized its biologic function. WDRPUH encodes
a predicted 620–amino acid protein containing 11
highly conserved WD40-repeat domains. Multiple-
tissue Northern blot analysis revealed its specific
expression in the testis among 16 normal tissues
examined. Transfection of plasmids designed to ex-
press WDRPUH-specific siRNA significantly reduced
its expression in HCC cells and resulted in growth
suppression of transfected cells. Interestingly, we
found that WDRPUH associated with HSP70, proteins
of the chaperonin-containing TCP-1 (CCT1) complex,
as well as BRCA2. These findings have disclosed a
novel insight into hepatocarcinogenesis and sug-
gested that WDRPUH may be a molecular target for
the development of new strategies to treat HCCs.
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Introduction
Hepatocellular carcinoma (HCC) is the fifth most common
neoplasm in the world [1], and its incidence is gradually in-
creasing in developed countries. It is the most common pri-
mary epithelial malignancy occurring in the liver. Although
recent medical advances have made great progress in its
diagnosis, many patients with HCC are not diagnosed until
the disease has reached an advanced stage. A wide variety
of chemotherapeutic agents as well as physical methods
that cause obstruction of tumor nutrition vessels or induce
necrosis of tumor cells with ethanol have been tried and are
in use to treat HCCs, but no regimen has proved sufficiently
to be curative and a substantial number of patients suffer
from severe adverse effects [2]. Therefore, development of
more effective chemotherapeutic drugs or chemoprevention
strategies is an urgent issue.
A new class of anticancer drugs that target a specific mo-
lecule has proved its effectiveness in the clinical field. For exam-
ple, imatinib, a small molecule that associates with the kinase
domain of bcr–abl fusion protein, is now applied for chronic
myelogenous leukemia and gastrointestinal stromal tumor that
frequently harbors an activating mutation in the c-kit protein.
Because these proteins play an essential role for their devel-
opment, imatinib showed striking effectiveness against the
growth of these neoplasms. Additionally, gefitinib, a drug that
was developed to compete with the binding of ATP to the intra-
cellular tyrosine kinase domain of epidermal growth factor re-
ceptor (EGFR), was utilized for non–small cell lung carcinoma
that expresses abundant EGFR [3]. Because EGFR mediates
growth-promoting signals from the extracellular domain by the
phosphorylation of downstream mediators, the inhibition of ki-
nase activity results in a drastic growth-suppressive effect on a
subset of lung cancers. These evidences strongly suggest that
genes that are exclusively expressed in tumors and involved in
their proliferation seem to be promising anticancer targets.
Epidemiologic studies have clarified that chronic liver inflam-
mation caused by viral infection and exposures to chemical
carcinogens are main risk factors for tumorigenesis. Accumu-
lating evidence from molecular studies suggests that multiple
processes involving qualitative and quantitative alterations
in several gene products underlie hepatocarcinogenesis.
Several growth factors including transforming growth
factor-a (TGF-a) [4,5] and insulin-like growth factor-2 (IGF-2)
have been implicated in the development of HCC. Altered
expression of a number of other genes such as E-cadherin,
MMP-1, MMP-7, MT1-MMP, gankyrin, and PEG10 may
also be involved in the development and/or progression of
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HCC [6,7]. In addition, tumor-suppressor genes such as p53,
AXIN1, and p16 INK4a play a crucial role in hepatocarcino-
genesis [8–10]. Regardless of all these findings, the com-
plete understanding of the molecular events that lead to the
development and progression of HCC is still far away.
In a previous study of genomewide analysis of gene
expression in HCC by cDNA microarray [11], we identified
165 genes upregulated in HCC. Among the 165 transcripts
in the list, we focused here on a gene encoding a novel WD-
repeat protein. Proteins containing WD repeats have been
reported to play crucial roles in a wide range of physiological
functions including signal transduction, RNA processing [12],
remodeling of cytoskeleton [13], regulation of vesicular traf-
ficking [14], and cell division [15]. For example, RACK1
protein containing seven WD40-repeats functions as an
anchor for protein kinase C (PKC) [16] in the PKC signal
transduction pathway. Another WD domain–containing pro-
tein, TRIP-1, specifically associates with the type II TGF-b
receptor in a kinase-dependent manner and mediates TGF-b
signaling [17]. The WD-40 domain of Cdc4p binds directly to
phospho-Sic1p and controls cell division by the recruitment of
Skp1p [15,18]. Other WD-repeat–containing proteins have
also been shown to be involved in a variety of functions [e.g.,
transcriptional regulation (TUPI), RNA processing (PRP4
and PRP17), cell cycle progression (CDC4 and CDC20),
and growth regulation (G protein b-subunits and MSII)] [19].
In the present study, we identified a novel gene with
growth-promoting activity, WDRPUH, which is overex-
pressed in a great majority of HCCs. Because suppression
of WDRPUH leads to growth retardation of cancer cells,
WDRPUH is a novel potential target for the development of
therapeutic strategies for HCC.
Materials and Methods
Cell Lines
Human embryonic kidney 293 (HEK293) cells were
obtained from IWAKI; human hepatoma cell lines Alexander
and HepG2, a testicular cancer cell line Tera-1, and mouse
fibroblast cell line NIH3T3 were from the American Type
Culture Collection (ATCC, Rockville, MD). Another human
hepatoma cell line, Huh7, was obtained from the Japanese
Collection of Research Bioresources (JCRB, Tokyo, Japan),
whereas SNU449 and SNU475 were obtained from the
Korea Cell Line Bank (KCLB Seoul, Korea). All cell lines
were grown in monolayers in appropriate media: Dulbecco’s
modified Eagle’s medium for Alexander, Huh7, HepG2, and
HEK293; RPMI 1640 for SNU423, SNU449, and SNU475;
and McCoy’s 5A for Tera-1, supplemented with 10% fetal
bovine serum and 1% antibiotic/antimycotic solution (Sigma,
St. Louis, MO). All cells were maintained at 37jC in humid air
with 5% CO2.
RNA Preparation and Reverse Transcription Polymerase
Chain Reaction (RT-PCR)
Total RNA was extracted with a Qiagen RNeasy
kit (Qiagen, Valencia, CA) or Trizol reagent (Invitrogen,
Carlsbad, CA) according to the manufacturers’ protocols.
Ten-microgram aliquots of total RNA were reversely tran-
scribed for single-stranded cDNA using poly dT12–18 primer
(Amersham Pharmacia Biotechnologies, Little Chalfont, UK)
with Superscript II reverse transcriptase (Invitrogen). Each
single-stranded cDNA preparation was diluted for sub-
sequent PCR amplification by standard RT-PCR experi-
ments carried out in 12.5-ml volumes of PCR buffer (Takara,
Otsu, Japan). Amplification proceeded for 4 minutes at
94jC for denaturing, followed by 35 cycles for WDRPUH
or 20 cycles for GAPDH, of 94jC for 30 seconds, 56jC
for 30 seconds, and 72jC for 45 seconds, in the GeneAmp
PCR system 9700 (Perkin-Elmer, Foster City, CA). Primer
sequences were: for GAPDH: forward, 5V-ACAACAG-
CCTCAAGATCATCAG-3V and reverse, 5V-GGTCCACC-
ACTGACACGTTG-3 V; for WDRPUH : forward, 5 V-
CAGGTGGAAATGACCATCTGGTCAAAG-3V and reverse,
5V-CATCAGCTTCAGGAGGTATATGGGTAC-3V.
Northern Blot Analysis
Human multiple-tissue blots (Clontech, Palo Alto, CA)
were hybridized with a 32P-labeled WDRPUH cDNA. Pre-
hybridization, hybridization, and washing were performed
according to the supplier’s recommendations. The blots
were autoradiographed with intensifying screens at 80jC
for 120 hours.
5 VRapid Amplification of cDNA Ends (5 VRACE)
5V RACE experiments were carried out using a Marathon
cDNA amplification kit (Clontech) according to the manu-
facturer’s instructions. For the amplification of the 5V part
of WDRPUH cDNA, a gene-specific reverse primer (5V-
TTACCGTCGTTCCATGCTGAAATGATGC-3V) and AP-1
primer supplied in the kit were used. The cDNA template
was synthesized from human testis mRNA (Clontech). The
PCR products were cloned using a TA cloning kit (Invitrogen,
Carlsbad, CA) and their sequences were determined with
an ABI PRISM 3700 DNA sequencer (Applied Biosystems,
Foster City, CA).
Construction of Plasmids Expressing WDRPUH
The entire coding region of WDRPUH was amplified by
RT-PCR using a set of gene-specific primers: 5V- GGGGT-
ACCACCATGGATAACAAAATTTCGCCGGAG-3V and 5V-
CGGAATTCTCAGGAGGTATATGGGTACTTCCATCG-3V.
The PCR products were cloned into an appropriate clon-
ing site of either pcDNA3.1 (Invitrogen), p3xFLAG-CMV-10
(Sigma), or pcDNA3.1myc/His (Invitrogen) vector.
Immunopreciptation
HEK293 cells that do not express WDRPUH were trans-
fected with p3xFLAG-WDRPUH, mock vector, or p3xFLAG-
SMYD3 (as a control). The cells were harvested at 48 hours
after transfection and lysed with Nonidet P40 lysis buffer
[20 mM Tris–HCl pH 7.5, 150 mMNaCl, 1% NP-40, 1 com-
plete Protease Inhibitor Cocktail EDTA () (Roche, Basel,
Switzerland)]. Cell lysates were immunoprecipitated with
anti–FLAG M2 antibody conjugated with agarose overnight
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at 4jC. After being washed five times with lysis buffer,
precipitated protein complex was eluted with 25 mg of FLAG
peptide for 1 hour at 4jC. The eluted complex was centri-
fuged and supernatant was resuspended in 5 Laemmli
sample buffer and separated by sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE).
Immunoblotting
Cells transfected with p3xFLAG-WDRPUH were washed
twice with PBS and lysed in lysis buffer (50 mM Tris–HCl,
pH 7.5, 25 M NaCl, 0.1% SDS, 5% NP40, and 1 complete
Protease Inhibitor Cocktail (Roche)). After the cells had been
homogenized and centrifuged at 10,000g for 15 minutes,
each supernatant was standardized for protein concentra-
tion by the Bradford assay (Bio-Rad, Hercules, CA). Proteins
were separated by 10% SDS-PAGE and immunoblotted
with mouse anti–FLAG M2 (Sigma) antibody, anti-HSP70
antibody (Stressgen, Victoria, Canada), anti–chaperonin-
containing TCP-1 (CCT1) delta subunity (Santa Cruz Bio-
technology, Santa Cruz, CA), anti–CTT1-alpha subunity
(Stressgen), or anti-BRCA2 (Stressgen). HRP-conjugated
goat anti-mouse IgG (Amersham Pharmacia Biotechnolo-
gies) served as the secondary antibody for the ECL Detec-
tion System (Amersham Pharmacia Biotechnologies).
Colony Formation Assay
PlasmidsexpressingWDRPUH (pcDNA-WDRPUH)or the
control vector (pcDNA-antisense-WDRPUH) were trans-
fected into NIH3T3 cells in triplicate. After 2 weeks of incu-
bation with an appropriate concentration of geneticin
(Invitrogen), cells were fixed with 100%methanol and stained
with Giemsa solution. The data were subjected to analysis of
variance (ANOVA) and Student’s t test.
Gene-Silencing Effect of WDRPUH sIRNA
The genomic fragment of snRNA U6 promoter region was
amplified by PCR using a set of primers, 5V-GGGGATCAGC-
GTTTGAGTAA-3Vand 5V-TAGGCCCCACCTCCTTCTAT-
3V. The product was ligated with a fragment of pcDNA3.0
vector containing the neomycin-resistant gene and con-
structed psiU6BX vector as described elsewhere [20]. Plas-
mids expressingWDRPUH siRNA were prepared by cloning
of double-stranded oligonucleotides into the psiU6BX
vector. The oligonucleotides used for WDRPUH siRNA
were: 5 V-CACCAATGTGATCTTCTCCAGGTGCTT-
CAAGAGAGCACCTGGAGAAGATCACATT-3 V and
5 V-AAAAAATGTGATCTTCTCCAGGTGCTCTCTT-
GAAGCACCTGGAGAAGATCACATT-3V for si-01; 5V-
CACCAAGGACACCAGTTTCTCGTAGTTCAA -
GAGACTACGAGAAACTGGTGTCCTT-3V and 5V-AAA-
AAAGGACACCAGTTTCTCGTAGTCTCTTGA -
ACTACGAGAAACTGGTGTCCTT-3 V for s i -02; 5 V-
CACCAAAGAGACGCTCATAGCGACTTTCAAGA-
GAAGTCGCTATGAGCGTCTCTTT-3 V and 5 V-AAA-
A A A AGAGACGC TC A T AGCGAC T T C T C T TG -
AAAGTCGCTATGAGCGTCTCTTT-3 for si-03; 5 V-
CACCAAGGATATCAGGGTGTGGCACTTCAAGA-
GAGUGCCACACCCTGATATCCTT-3V and 5V-AAAA-
AGGATATCAGGGTGTGGCACTCTCTTGAAGTGCCA-
CACCCTGATATCCTT-3V for si-04. The single-stranded
oligonucleotides were phosphorylated with T4 polynucleotide
kinase, and forward and corresponding reverse oligo-
nucleotides were annealed after denaturation by boiling.
Double-stranded oligonucleotides were ligated into psi-
U6BX to create an expression vector expressing siRNA.
psiU6BX-WDRPUH, psiU6BX-EGFP, and psiU6BX-mock
(empty) plasmids were transfected into HepG2 and Alex-
ander cells using a FuGENE6 reagent according to the sup-
plier’s recommendations (Roche). Total RNA was extracted
from the cells 48 hours after transfection. Silencing of the
WDRPUH gene by the specific constructs was confirmed
by RT-PCR.
Cell Viability Assays
Cells were plated at a density of 5  105 cells/100 mm
dish. At 24 hours after seeding, the cells were transfected
in triplicate with psiU6BX-WDRPUH, EGFP, or mock plas-
mids using FuGENE6 (Roche) and subsequently maintained
with an appropriate concentration of G418. At 7 days after
transfection, the medium was replaced with fresh medium
containing 500 mg/ml (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyl tetrazolium bromide) (Sigma) and the plates were
incubated for 4 hours at 37jC. Subsequently, the cells were
lysed by the addition of 0.01 N HCl/10% SDS, and absor-
bance of lysates was measured with an ELISA plate reader
at a test wavelength of 570 nm (reference, 630 nm). The cell
viability was represented by the absorbance compared to
that of control cells. The data were subjected to ANOVA
and Student’s t test.
Matrix-Assisted Laser Desorption/Ionization Time of Flight
(MALDI-TOF) Mass Spectrometry Analysis
Proteins immunoprecipitated with anti-FLAG antibody
from cells transfected with plasmid p3xFLAG-WDRPUH
were separated by SDS-PAGE. We also prepared a
p3xFLAG-SMYD3 plasmid expressing an unrelated protein
and transfected it, or mock vector as controls, and obtained
immunoprecipitants with anti-FLAG. Associated proteins
were separated by SDS-PAGE, stained with Sypro-Ruby
(Bio-Rad), and compared by the bands between WDRPUH
and the unrelated protein. Specific bands stained by Sypro-
Ruby were excised and digested with trypsin as previously
described [21]. In the gel, tryptic digest was analyzed
by MALDI-TOF mass spectrometry analysis at Shimadzu
Biotechnologies (Tokyo, Japan). The mass spectral data
were evaluated using the Mascot search engine (http://
www.matrixscience.com) to identify proteins from primary
sequence databases.
Results
Identification of a Novel Human Gene Upregulated in HCC
We previously analyzed expression profiles of 20 HCC
tissues by the cDNA microarray, and compared them with
expression profiles of their corresponding noncancerous
350 Involvement of WDRPH in Hepatocellular Carcinoma Silva et al.
Neoplasia . Vol. 7, No. 4, 2005
liver tissues [11]. Out of 23040 genes screened by the array
slides, 165 transcripts were frequently upregulated in the
HCCs [11]. Among the 165 genes, we focused on a novel
gene with an in-house accession name of D3197 because
the gene was overexpressed in 11 of 12 HCCs that passed
our cutoff filter (data not shown). The gene corresponded
to an EST archived as Hs.232270, and was annotated
as LOC146845 in the UniGene database of the National
Center for Biotechnology Information. Consistent with the
microarray data, semiquantitative RT-PCR corroborated
its elevated expression in 8 of 10 additional HCC tissues
(Figure 1A). We also analyzed its expression in hepatoma
cell lines (Figure W1). Expression of the gene was not
frequently elevated in breast, colon, bladder, or prostate
cancer in our microarray data (data not shown).
Expression, Isolation, and Characterization of the
Novel Gene
Analysis with multiple-tissue Northern blots using the
D3197 cDNA as a probe revealed a 2.2-kb transcript that
was abundantly expressed in the testis (Figure 1B). Expres-
sion of this transcript was not detected in any other of the
15 organs examined. Because no EST clones containing the
5V part of this gene were identified in public databases, we
searched the genomic sequence encompassing the gene
in human genome sequence and obtained a sequence
(GenBank accession no. BC025392) that had been as-
signed to chromosomal band 17p13.1. Using GENSCAN and
the Gene Recognition and Assembly Internet Link (GRAIL)
program, with the genomic sequences, candidate exon se-
quences were predicted. Additional exon connection experi-
ments as well as 5V RACE determined the sequence of the 5V
part of the transcript, and obtained an assembled cDNA
sequence of 2152 nucleotides that contained an open read-
ing frame encoding a 620–amino acid protein (GenBank
accession no. AB065281). The gene consisted of 14 exons
spanning approximately 60 kb on the chromosomal band
17p13.1. The Simple Modular Architecture Research Tool
(SMART) program suggested that the predicted protein
contained 11 WD40-repeat domains. Thus, we termed the
gene as WDRPUH (WD40-repeat protein upregulated in
HCC). A homology search with WDRPUH amino acid se-
quence in public databases identified several homologous
proteins, including a mouse protein (accession no. NP_
082239), a rat protein (accession no. XP_220582), and a
hypothetical Macaca fascicularis protein (accession no.
BAB63111), which shared 88%, 89%, and 84% identity with
WDRPUH, respectively. These homologous proteins were
unnamed, hypothetical, or WD-repeat proteins, and their
functions remained to be clarified.
Subcellular Localization of WDRPUH
We prepared plasmids expressing Myc-taggedWDRPUH
and transiently transfected them into SNU475 and HepG2
hepatoma cells, and Tera-1 testicular tumor cells. Immuno-
blot analysis using extracts from HEK293 cells transfected
with the plasmid showed a 70-kDa band corresponding to the
tagged WDRPUH protein (Figure 2A). Immunocytochemical
staining of the SNU475, HepG2, and Tera-1 cells revealed
that the tagged WDRPUH protein was present in their cyto-
plasms by fluorescentmicroscopy (Figure 2B). The PSORT II
program consistently predicted the subcellular localization of
WDRPUH protein in the cytoplasm with 69.6% probability,
and did not predict any nuclear localization signals (data
not shown).
Growth-Promoting Effect of WDRPUH
To investigate the effect of WDRPUH on cell growth,
we carried out a colony formation assay by transfecting
NIH3T3 cells with a plasmid-expressing WDRPUH (pcDNA-
WDRPUH). When compared to cells transfected with a mock
plasmid (pcDNA) or those with control plasmid expressing
the complementary strand ofWDRPUH (pcDNA-antisense),
transfection with pcDNA-WDRPUH markedly increased the
number of colonies in NIH3T3 cells (Figure 3A), suggesting
that the elevated expression of WDRPUH may promote the
growth of cells. This observation was confirmed by three
independent experiments.
Figure 1. Expression of D3197 (WDRPUH). (A) Semiquantitative RT-PCR analysis of WDRPUH in 10 HCCs (T) and their corresponding noncancerous liver tissues
(N). Expression of GAPDH served as a control. (B) Northern blot analysis of WDRPUH in a panel of 16 adult normal human tissues. -Actin served as a control.
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Effect of WDRPUH Suppression on the Viability of
Cancer Cells
To test whether elevated expression of WDRPUH may
play a crucial role in the proliferation of HCC cells, we
prepared plasmids expressing four kinds of siRNA to
WDRPUH together with a neomycin-resistant gene, and
transfected them into HepG2 cells that expressedWDRPUH
abundantly (Figure W1). As shown in Figure 3B, plasmid-
expressing si-01 most effectively suppressed the expression
of WDRPUH compared with that of mock (psiU6BX) and
EGFP (psiU6BX-EGFP) controls, whereas other WDRPUH
siRNAs showed no or mild gene-silencing effect. Subse-
quently, to test whether suppression ofWDRPUHmay result
in growth retardation and/or cell death, we transfected
HepG2 cells with these plasmids and examined the growth
of transfected cells cultured in media containing an ap-
propriate concentration of G418, a derivative of neomycin,
by MTT assay. Interestingly, transfection of si-01 into
HepG2 cells reduced their viability when compared with
cells transfected with mock or EGFP (Figure 3C). However,
si-02, si-03, and si-04 showed a mild decrease in the num-
ber of surviving cells compared with cells transfected with
si-01 (Figure 3C), indicating that suppressed expression
of WDRPUH associates with a decrease in cell viability,
either by reduction of cell growth or induction of apoptosis.
We also investigated the effect of si-01 in Alexander HCC
cells, which revealed similar results (Figure 3D). These
data suggest that WDRPUH may play an essential role in
the growth or survival of HCC cells.
Identification of WDRPUH Interacting Proteins by
Immunoprecipitation Mass Spectrometry (IP-MS)
To investigate the biologic function of WDRPUH, we
searched its interacting protein(s) by IP-MS. We transfected
HEK293 cells, with plasmids expressing FLAG-tagged
WDRPUH, empty vector (mock), or plasmid designed to
express an unrelated FLAG-tagged protein. After the incu-
bation of cells, we then immunoprecipitated the proteins
using an anti-FLAG antibody conjugated with agarose beads.
Comparison of the bands on SDS-PAGE among the immuno-
precipitants from these cells identified three bands cor-
responding to proteins of 70, 58, and >250 kDa, which were
specifically immunoprecipitated in cells transfected with
p3XFLAG-WDRPUH. These bands were excised and sub-
sequently analyzed by MALDI mass spectrometry. The
70-kDa protein was found to be HSP70, the 58-kDa protein
was identified as the CCT1-y, a subunit of the CCT1 protein
complex, and the >250-kDa protein was disclosed to be
BRCA2 (data not shown). Using anti-FLAG antibody, we
immunoprecipitated extracts from cells transfected with
p3XFLAG-WDRPUH or mock vector, and confirmed that
HSP70 was coimmunoprecipitated from cells with p3XFLAG-
WDRPUH, but not from those with mock vector (Figure 4A).
Conversely, immunoprecipitaion with anti-HSP70 antibody
coimmunoprecipitated FLAG-tagged WDRPUH from cells
transfected with p3XFLAG-WDRPUH, but not those with
mock (Figure 4B). These results indicated the association
between WDRPUH and HSP70. Furthermore, we examined
the interaction between exogenous WDRPUH and endo-
genous CCT1-y in HEK293 cells. After immunoprecipitation
of FLAG-tagged WDRPUH with anti-FLAG antibody,
we performed immunoblotting with CCT1-y antibody and
identified a band of 58 kDa confirming their association
(Figure 4C). In addition, we detected the association of
WDRPUH with CCT1-a subunit by Co-IP, showing that
WDRPUH associates with both a and y subunits of CCT
complex proteins (Figure 4D). We also confirmed the as-
sociation between WDRPUH and BRCA2 in HEK293 cells
(Figure 4E ), as well as HeLa cells (data not shown). In
addition, immunoprecipitation with anti-BRCA2 antibody
coimmunoprecipitated FLAG- tagged WDRPUH from
cells transfected with p3XFLAG-WDRPUH, but not those
with mock vector (Figure 4F ). However, because Hek293
cells do not express endogenous WDRPUH, tissue-specific
Figure 2. Subcellular localization of WDRPUH. (A) Western blot analysis of exogenously expressed Myc-tagged WDRPUH protein in HEK293 cells. Empty
pcDNA3.1myc/His (mock) vector was used as a negative control. (B) Myc-tagged WDRPUH protein was expressed exogenously into SNU475 and HepG2
hepatoma cells and in Tera-1 testicular cancer cells, and stained with anti-Myc monoclonal antibody. The protein was visualized by FITC-conjugated secondary
anti –mouse IgG antibody (left panel). Nuclei were counterstained with DAPI (middle panel). Merged image of FITC and DAPI (right panel).
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differences may exist in binding partners in normal testes
and hepatomas.
Discussion
In the study presented here, we characterized a novel gene,
WDRPUH, which was frequently upregulated in the majority
of HCCs, and demonstrated its possible involvement in
cancer proliferation. Moreover, we revealed that WDRPUH
protein interacts with HSP70 and the CCT chaperonin com-
plex proteins as well as the tumor-suppressor protein BRCA2.
WDRPUH encodes a putative 620–amino acid protein
with 11 highly conserved WD40-repeat domains. Struc-
tural analysis has clarified that WD-repeat proteins form a
propeller-like structure with several blades that is composed
of a four-stranded antiparallel b-sheet. This b-propeller– like
structure serves as a platform to which proteins can bind
either stably or reversibly [22]. The number of blades in the
b-propeller– like structure varies depending on the number of
WD-repeats that are structural elements of the b-propeller.
Therefore, WDRPUH should form a propeller-like structure
with 11 blades responsible for its interaction with other pro-
teins. Among other WD-repeat proteins, endonuclein con-
taining five WD-repeat domains was also shown to be
upregulated in pancreatic cancer [23]. Although immuno-
histochemical staining of endonuclein revealed that its sub-
cellular localization was in the nucleus as well as in the
endoplasmic reticulum, the functions of endonuclein have
not yet been elucidated. Another WD-repeat protein, beta-
transducin repeat-containing protein (BTRC), contains an
F-box and sevenWD-repeats, and functions as a component
of SCF (SKIP1, CUL1, and F-protein) complex that degrades
IkappaBalpha and b-catenin [24]. A recent report revealed
that Btrc null mice showed hypoplasia of mammary glands,
and that transgenic mice expressing human BTRC in mam-
mary gland conversely displayed increased ductal branch-
ing, leading to the development of mammary tumors [25].
Similarly, accumulated WDRPUH may play a role in devel-
opment of tumors through unidentified mechanism(s).
In normal tissues examined, WDRPUH is highly ex-
pressed in the testis, but not in other normal organs exam-
ined, which suggests that WDRPUH may be involved in
spermatogenesis. Alternatively, WDRPUH may play a role
of maintenance of progenitor properties of spermatocytes
Figure 3. Growth-promoting effect of WDRPUH. (A) Colony formation assay of WDRPUH in NIH3T3 cells. Cells transfected with pcDNA-WDRPUH, pcDNA-
WDRPUH-antisense strand, or pcDNA (mock) were culturedwith an appropriate concentration ofG418 and stainedwithGiemsa solution. The number of colonieswas
counted by electric densitometry in a triplicate experiment of colony formation assay. *A significant difference (P < .05) determined by Student’s t test. (B) Gene
knockdown effect of plasmids expressing four different WDRPUH-siRNA or EGFP-siRNA, and mock plasmid. Semiquantitative RT-PCR was carried out to examine
the expression of WDRPUH, 48 hours after the transfection of the plasmids in HepG2 cells. (C) Effect of WDRPUH-siRNA on the growth of HepG2 cells. Viability of
HepG2 cells transfected withWDRPUH-siRNAwas analyzed in triplicate usingMTT assay at day 7 after the transfection and subsequent maintenance of cells with an
appropriate concentration of G418. (D) Effect ofWDRPUH-siRNA on the growth of Alexander cells was analyzed as described in (C). *A significant difference (P < .05)
determined by Student’s t test.
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because cancers are thought to include some character-
istics of progenitor cells [26]. These views may help future
studies to reveal the physiological function ofWDRPUH in the
testis. In addition, because its expression is enhanced inHCC
tissues, WDRPUH may be a novel cancer–testis antigen.
Therefore, immunotherapies targeting WDRPUH may be a
novel therapeutic option.
A number of proteins containing WD40-repeats bind to
CCT complex. A proteomic analysis demonstrated that
among the 21 CCT-interacting proteins in yeast cells, 16 pro-
teins commonly possessed WD40 motifs [27]. CCT is a
molecular chaperone with a double toroidal structure that
contains a central cavity in which protein folding and the
achievement of the correct conformation of newly translated
proteins are assisted [28]. For example, Camasses et al. [29]
have elegantly shown that the central cavity of CCT pre-
vents nonnative interactions of the nascent WD-repeats of
Cdc20, which in turn facilitates its native association with
the WD-repeats. Because WDRPUH also interacts with
CCT through its a and y subunits, the functional structure
of WDPURH protein and/or its stability may be achieved
and maintained by CCT. It may be possible that CCT also
exerts a different role from the maintenance of WDRPUH
protein structure because it also regulates the activity of
WD-repeat–containing proteins by controlling their libera-
tion into the cytosol or binding to other proteins in assembly,
such as with the Von Hippel-Lindal (VHL) protein elongin
BC (VBC) tumor-suppressor complex formation [30]. The
VHL–VBC complex was also shown to interact with both
CCT and HSP70 on expression in mammalian cells [31].
Consistent with reports that CCT interacts with HSP70
either directly [28] or through interaction with the HSP70/
HSP90 organizing protein [31], we further identified HSP70
as another WDRPUH-interacting protein but failed to detect
association with HSP90 (data not shown). Because a CCT–
HSP70 complex was shown to mediate the folding of some
newly synthesized proteins [32,33], these chaperones may
cooperate to stabilize the conformation of WDRPUH and
keep the high level of WDRPUH in HCC cells. Future studies
will be required to clarify the role of these chaperones in the
function of WDRPUH.
Our experiments revealed an association of WDRPUH
with BRCA2. BRCA2 plays an important role in DNA repair
by direct binding through its BRC repeats to the DNA repair
protein, RAD51 [34,35]. In addition, a protein complex of
BRCA2 and BRAF35 was suggested to play a significant role
in the regulation of cell cycle progression [36]. Disruption of
associations of BRCA2 with BRCA2-binding partners could
compromise the DNA repair functions of RADS1, or alter the
functions of other binding partners [37]. Combining the facts
that WDRPUH was transactivated in HCC cells and inter-
acted with BRCA2, we hypothesize that elevated expression
of WDRPUH may abrogate transcriptional modulation, DNA
repair, or control of cell cycle progression through the in-
terference of the binding between BRCA2 and its inter-
acting proteins including RAD51, BRAF35, or others.
Because WDRPUH is localized in the cytoplasm, its inter-
action to BRCA2 may impair the translocation of BRCA2 into
the nucleus. Therefore, it is interesting to test whether growth
promotion by WDRPUH in HCC cells depends on the inter-
action between WDRPUH and BRCA2.
In this report, we revealed that the expression of
WDRPUH was enhanced in the majority of HCC tissues.
Because it is very low or absent among all the vital organs
and its elevated expression was associated with growth of
HCC cells, suppression of WDRPUH may be an optional
therapeutic strategy for treating primary HCCs. Because it is
evidenced that WDRPUH interacts with HSP70 and CCT as
well as BRCA2, the impairment of these interactions impli-
cates a possible strategy to inhibit the function of WDRPUH.
Although additional functional analyses of WDRPUH are
required, the findings provided here should contribute to a
Figure 4. Interaction ofWDRPUHwith HSP70, CCT1-d, CCT1-a, or BRCA2. HEK293 cells were transiently transfected with p3xFLAG-WDRPUH or p3xFLAG empty
vector (Mock). Cell lysates were immunoprecipitated with anti –FLAG M2 antibody (mouse) conjugated with agarose beads or specific antibodies to interacting
protein. (A and B) Coimmunoprecipitation of FLAG-WDRPUH and endogenous HSP70. Whole cell extracts from the cells exogenously expressing FLAG-WDRPUH
were used as positive controls. (C) Coimmunoprecipitation of FLAG-WDRPUH and endogenous CCT1-d. (D) Coimmunoprecipitation of FLAG-WDRPUH and
endogenous CCT1-a. (E and F) Coimmunoprecipitation of FLAG-WDRPUH and endogenous BRCA2.
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novel insight in hepatocarcinogenesis and to the develop-
ment of novel therapeutic approaches to HCC.
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